Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
Want to see IOVA full AI Analyst Report?
IOVA Stock Chart & Stats
$3.86
-$0.33(-4.53%)
At close: 4:00 PM EST
$3.86
-$0.33(-4.53%)
Day’s Range― - ―
52-Week Range$1.64 - $5.63
Previous CloseN/A
Volume2.95M
Average Volume (3M)14.80M
Market Cap
$1.59B
Enterprise Value$1.14B
Total Cash (Recent Filing)$313.44M
Total Debt (Recent Filing)$46.78M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding446,502,400
10 Day Avg. Volume17,222,516
30 Day Avg. Volume14,795,721
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue4.01
Enterprise Value/Gross Profit3.50
Enterprise Value/Ebitda-3.50
Forecast
1Y Price Target
$8.44Price Target Upside118.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$364.00M
Bulls Say, Bears Say
Bulls Say
Commercial MomentumGrowing demand for AMTAGVI and repeated distributor reorders of Proleukin support sustained revenue growth as more patients gain treatment access.
Pipeline And Regulatory ProgressProgress toward a regulatory filing in non-small cell lung cancer and expansion into lung, sarcoma, and endometrial indications provide clear pathways for additional product launches and broader sales.
Profitability And MarginsImproved patient use and better manufacturing raised gross margins, enhancing profitability potential as treatment volumes expand.
Bears Say
Capital Structure And DilutionPotential increases in share count could dilute earnings per share and create downward pressure on reported quarterly results.
Market SentimentPersistent investor skepticism about the tumor‑infiltrating lymphocyte approach keeps sentiment cautious and may cap valuation until confirmatory melanoma results are available.
Sales Forecast RiskAnalyst cuts to AMTAGVI sales estimates highlight downside risk to revenue projections if commercial traction slows.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $1.64 and its highest was $5.63 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $1.59B.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 84 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.154 by -$0.036.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.13.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 446,502,400 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.154. Following the earnings report the stock price went down -13.203%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in IOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.44 (118.77% Upside)
$8.44 (118.77% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 86%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 152.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.14%
12-Months-Change
Fundamentals
Return on Equity
-50.17%
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IOVA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress: high single-quarter revenue growth (~45% YoY), robust Amtagvi demand (+38% YoY), tighter Q2/full-year guidance, expanded manufacturing control, R&D cost reductions, extended cash runway into 2028, and encouraging early clinical signals (e.g., 40% ORR in serous endometrial cancer). Near-term headwinds include a one-time facility-related margin hit (Q1 gross margin ~41%), some quarter-to-quarter revenue volatility in Proleukin, continued use of ATM financing, and the usual clinical/regulatory and enrollment execution risks. Overall, the positives—notably accelerating commercial traction, pipeline advances, and improved cost discipline—substantially outweigh the listed challenges.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$8.44
▲(118.77% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
0.32% Insiders
10.51% Mutual Funds
2.20% Other Institutional Investors
72.68% Public Companies and Individual Investors